Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cannabinoid receptor 1 (brain) | Starlite/ChEMBL | References |
Homo sapiens | cannabinoid receptor 2 (macrophage) | Starlite/ChEMBL | References |
Rattus norvegicus | Cannabinoid CB2 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 330 aa | 20.9 % | |
Echinococcus granulosus | allatostatin A receptor | Cannabinoid CB2 receptor | 360 aa | 363 aa | 22.9 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Cannabinoid CB2 receptor | 360 aa | 370 aa | 23.8 % |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 327 aa | 19.6 % | |
Schistosoma mansoni | opsin-like receptor | Cannabinoid CB2 receptor | 360 aa | 314 aa | 22.0 % |
Schistosoma mansoni | peptide (allatostatin)-like receptor | Cannabinoid CB2 receptor | 360 aa | 323 aa | 22.6 % |
Echinococcus multilocularis | allatostatin A receptor | Cannabinoid CB2 receptor | 360 aa | 342 aa | 22.8 % |
Loa Loa (eye worm) | neuropeptide F receptor | Cannabinoid CB2 receptor | 360 aa | 348 aa | 24.7 % |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Cannabinoid CB2 receptor | 360 aa | 360 aa | 23.1 % |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 297 aa | 21.9 % | |
Onchocerca volvulus | Phospholipase d-related homolog | Cannabinoid CB2 receptor | 360 aa | 309 aa | 23.3 % |
Echinococcus granulosus | neuropeptide receptor | Cannabinoid CB2 receptor | 360 aa | 337 aa | 24.0 % |
Onchocerca volvulus | Cannabinoid CB2 receptor | 360 aa | 389 aa | 21.1 % | |
Schistosoma mansoni | biogenic amine (5HT) receptor | Cannabinoid CB2 receptor | 360 aa | 370 aa | 23.5 % |
Echinococcus multilocularis | neuropeptide receptor | Cannabinoid CB2 receptor | 360 aa | 299 aa | 24.7 % |
Schistosoma japonicum | ko:K04209 neuropeptide Y receptor, invertebrate, putative | Cannabinoid CB2 receptor | 360 aa | 311 aa | 20.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | integrin linked protein kinase | 0.0956 | 1 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0016 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0016 | 0 | 0.5 |
Trichomonas vaginalis | TKL family protein kinase | 0.0016 | 0 | 0.5 |
Trichomonas vaginalis | ankyrin repeat-containing protein, putative | 0.0016 | 0 | 0.5 |
Entamoeba histolytica | ankyrin repeat protein | 0.0016 | 0 | 0.5 |
Echinococcus multilocularis | integrin linked protein kinase | 0.0956 | 1 | 1 |
Onchocerca volvulus | 0.0016 | 0 | 0.5 | |
Loa Loa (eye worm) | TKL/MLK/ILK protein kinase | 0.0956 | 1 | 1 |
Schistosoma mansoni | protein kinase | 0.0956 | 1 | 1 |
Trichomonas vaginalis | TKL family protein kinase | 0.0016 | 0 | 0.5 |
Giardia lamblia | Protein 21.1 | 0.0016 | 0 | 0.5 |
Giardia lamblia | Kinase, NEK | 0.0016 | 0 | 0.5 |
Trichomonas vaginalis | TKL family protein kinase | 0.0016 | 0 | 0.5 |
Trichomonas vaginalis | TKL family protein kinase | 0.0016 | 0 | 0.5 |
Schistosoma mansoni | protein kinase | 0.0956 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | > 5 | Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in CHO cells after 90 mins | ChEMBL. | 22370265 |
Ki (binding) | = 6.58 | Displacement of [3H]CP-55940 from rat recombinant CB2 receptor expressed in HEK293 cells after 90 mins | ChEMBL. | 22370265 |
Ki (binding) | = 6.92 | Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cells after 90 mins | ChEMBL. | 22370265 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.